Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

Introduction: Despite initial benefit, virtually all patients suffering from EGFR-mutant NSCLC experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by multiple mechanisms. Recent reports have identified oncogenic kinase fusions as off-target resistance mechanisms; however, the...

Full description

Bibliographic Details
Main Authors: Diego Enrico, MD, Ludovic Lacroix, PharmD, PhD, Jeanne Chen, MD, Etienne Rouleau, PharmD, PhD, Jean-Yves Scoazec, MD, PhD, Yohann Loriot, MD, PhD, Lambros Tselikas, MD, Cécile Jovelet, PharmD, PhD, David Planchard, MD, PhD, Anas Gazzah, MD, Laura Mezquita, MD, PhD, Maud Ngo-Camus, MSc, Stefan Michiels, PhD, Christophe Massard, MD, PhD, Gonzalo Recondo, MD, PhD, Francesco Facchinetti, MD, Jordi Remon, MD, Jean-Charles Soria, MD, PhD, Fabrice André, MD, PhD, Gilles Vassal, MD, PhD, Luc Friboulet, PhD, Benjamin Besse, MD, PhD
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR resistance
Oncogene fusions
NSCLC
EGFR tyrosine kinase inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320300230

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320300230

Similar Items